Matthew S. Brown

Dr. Matthew S. Brown


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Radiology
Verified
Journal Article
Closed access
MBMatthew S. Brown
Matthew S. Brown
JGJonathan G. Goldin
Jonathan G. Goldin
RSRobert D. Suh
Robert D. Suh
MMMichael McNitt-Gray
Michael McNitt-Gray
JSJames W. Sayre
James W. Sayre
DADenise R. Aberle
Denise R. Aberle
An automated system was developed for detecting lung micronodules on thin-section computed tomographic images and was applied to data from 15 subjects with 77 lung nodules. The automated system, without user interaction, achieved a sensitivity of 100% for nodules (>3 mm in diameter) and 70% for micronodules (


1 June 2005 in Academic Radiology
Verified
Journal Article
Closed access
MBMatthew S. Brown
Matthew S. Brown
JGJonathan G. Goldin
Jonathan G. Goldin
SRSarah Rogers
Sarah Rogers
HKHyun J. Kim
Hyun J. Kim
RSRobert D. Suh
Robert D. Suh
DADenise R. Aberle
Denise R. Aberle

1 May 2023 in RadioGraphics
Verified
Journal Article
Closed access
YCYoungwon Choi
Youngwon Choi
WYWenxi Yu
Wenxi Yu
MNMahesh B. Nagarajan
Mahesh B. Nagarajan
PTPangyu Teng
Pangyu Teng
JGJonathan G. Goldin
Jonathan G. Goldin
MBMatthew S. Brown
Matthew S. Brown
To translate artificial intelligence (AI) algorithms into clinical practice requires generalizability of models to real-world data. One of the main obstacles to generalizability is data shift, a data distribution mismatch between model training and real environments. Explainable AI techniques offer tools to detect and mitigate the data shift problem and develop reliable AI for clinical practice. Most medical AI is trained with datasets gathered from limited environments, such as restricted disease populations and center-dependent acquisition conditions. The data shift that commonly exists in the limited training set often causes a significant performance decrease in the deployment environment. To develop a medical application, it is important to detect potential data shift and its impact on clinical translation. During AI training stages, from premodel analysis to in-model and post hoc explanations, explainability can play a key role in detecting model susceptibility to data shift, which is otherwise hidden because the test data have the same biased distribution as the training data. Performance-based model assessments cannot effectively distinguish the model overfitting to training data bias without enriched test sets from external environments. In the absence of such external data, explainability techniques can aid in translating AI to clinical practice as a tool to detect and mitigate potential failures due to data shift. ©RSNA, 2023 Quiz questions for this article are available in the supplemental material.

24 July 2014 in European Radiology
Verified
Journal Article
Closed access
PDF file
MBMatthew S. Brown
Matthew S. Brown
PLPechin Lo
Pechin Lo
JGJonathan G. Goldin
Jonathan G. Goldin
EBEran Barnoy
Eran Barnoy
GKGrace Hyun J. Kim
Grace Hyun J. Kim
DADenise R. Aberle
Denise R. Aberle

1 April 2012 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
MBMatthew S. Brown
Matthew S. Brown
GCGregory H. Chu
Gregory H. Chu
HKHyun J. Kim
Hyun J. Kim
MAMartin Allen-Auerbach
Martin Allen-Auerbach
CPCheryce Poon
Cheryce Poon
JGJonathan G. Goldin
Jonathan G. Goldin
Objective The development and evaluation of a computer-aided bone scan analysis technique to quantify changes in tumor burden and assess treatment effects in prostate cancer clinical trials. Methods We have developed and report on a commercial fully automated computer-aided detection (CAD) system. Using this system, scan images were intensity normalized, and then lesions were identified and segmented by anatomic region-specific intensity thresholding. Detected lesions were compared against expert markings to assess the accuracy of the CAD system. The metrics Bone Scan Lesion Area, Bone Scan Lesion Intensity, and Bone Scan Lesion Count were calculated from identified lesions, and their utility in assessing treatment effects was evaluated by analyzing before and after scans from metastatic castration-resistant prostate cancer patients: 10 treated and 10 untreated. In this study, patients were treated with cabozantinib, a MET/vascular endothelial growth factor inhibitor resulting in high rates of resolution of bone scan abnormalities. Results Our automated CAD system identified bone lesion pixels with 94% sensitivity, 89% specificity, and 89% accuracy. Significant differences in changes from baseline were found between treated and untreated groups in all assessed measurements derived by our system. The most significant measure, Bone Scan Lesion Area, showed a median (interquartile range) change from baseline at week 6 of 7.13% (27.61) in the untreated group compared with −73.76% (45.38) in the cabozantinib-treated group (P=0.0003). Conclusion Our system accurately and objectively identified and quantified metastases in bone scans, allowing for interpatient and intrapatient comparison. It demonstrates potential as an objective measurement of treatment effects, laying the foundation for validation against other clinically relevant outcome measures.